Does IgE Bind to and Activate Eosinophils from Patients with Allergy?
Author:
Kita Hirohito1, Kaneko Masayuki1, Bartemes Kathleen R.1, Weiler Deborah A.1, Schimming Andrew W.1, Reed Charles E.1, Gleich Gerald J.1
Affiliation:
1. Departments of Immunology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905
Abstract
Abstract
Human eosinophils have been reported to express both the mRNA and protein for the high affinity IgE receptor (FcεRI); it is speculated that this receptor plays a role in eosinophil mediator release in allergic diseases. However, questions still remain. How much of the FcεRI protein is actually expressed on the cell surface of the eosinophil? If they are present, are these IgE receptors associated with effector functions of eosinophils? To address these issues, we studied blood eosinophils from patients with ragweed hay fever. A high level of low affinity IgG receptor (FcγRII, CD32), but no expression of FcεRI, was detectable on the eosinophil surface by standard FACS analysis. However, after in vitro sensitization with biotinylated chimeric IgE (cIgE), cell-bound cIgE was detected by PE-conjugated streptavidin. This cIgE binding was partially inhibited by anti-FcεRI mAb, suggesting that eosinophils do express minimal amounts of FcεRI detectable only by a sensitive method. Indeed, FACS analysis of whole blood showed that eosinophils express ∼0.5% of the FcεRI that basophils express. When stimulated with human IgE or anti-human IgE, these eosinophils did not exert effector functions; there was neither production of leukotriene C4 or superoxide anion nor any detectable degranulation response. In contrast, eosinophils possessed membrane-bound human IgG and showed functional responses when stimulated with human IgG or anti-human IgG. Thus, IgG and/or cytokines, such as IL-5, appear to be more important for eosinophil activation in allergic diseases than IgE.
Publisher
The American Association of Immunologists
Subject
Immunology,Immunology and Allergy
Reference54 articles.
1. Butterfield, J. H., K. M. Leiferman, G. J. Gleich. 1995. Eosinophil-associated diseases. M. M. Frank, and K. F. Austen, and H. N. Claman, and E. R. Unanue, eds. In Samter’s Immunologic Diseases Vol. 1: 501 Little, Brown, Boston. 2. Kita, H., C. R. Adolphson, G. J. Gleich. 1998. Biology of eosinophils. E. Middleton, Jr, and C. E. Reed, Jr, and E. F. Ellis, Jr, and N. F. Adkinson, Jr, and J. W. Yunginger, Jr, and W. W. Busse, Jr, eds. Allergy: Principles and Practice 5th Ed.242 Mosby-Year Book, St. Louis. 3. Lee, T.-C., D. J. Lenihan, B. Malone, L. L. Roddy, S. I. Wasserman. 1984. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J. Biol. Chem. 259: 5526 4. Sedgwick, J. B., R. F. Vrtis, M. F. Gourley, W. W. Busse. 1988. Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils. J. Allergy Clin. Immunol. 81: 876 5. Abu-Ghazaleh, R. I., T. Fujisawa, J. Mestecky, R. A. Kyle, G. J. Gleich. 1989. IgA-induced eosinophil degranulation. J. Immunol. 142: 2393
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|